This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.
Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC
CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but
Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS
Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance. ... I am delighted that patients can maintain long term access to Brentuximab
Keytruda is cleared for use in adults who have failed a stem cell transplant and have already tried or are ineligible for Takeda's Adcetris (brentuximab vedotin).
brentuximab vedotin), so Merck is playing catch-up in this indication. ... prior stem cell transplantation or use of brentuximab vedotin.".
More from news
Approximately 3 fully matching, plus 25 partially matching documents found.
Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...